GATA2 as a potential metastasis-driving gene in prostate cancer

Oncotarget

Volumn 5, Issue 2, 2014, Pages 451-461

  Chiang, Yan Ting ^a,b   Wang, Kendric ^b   Fazli, Ladan ^b   Qi, Robert Z ^c   Gleave, Martin E ^b   Collins, Colin C ^b   Gout, Peter W ^a   Wang, Yuzhuo ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Focal adhesion; GATA2 gene; Master regulatory gene; Metastasis; Prostate cancer

Indexed keywords

TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTOME; GATA2 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FOCAL ADHESION; GATA2 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; METASTASIS; NONHUMAN; PROSTATE CANCER; TRANSCRIPTION REGULATION; UPREGULATION; CASTRATION RESISTANT PROSTATE CANCER; CELL MOTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; FOCAL ADHESIONS; GATA2 TRANSCRIPTION FACTOR; GENE SILENCING; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSCRIPTOME; TRANSFECTION;

EID: 84896724167     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1296     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. Jama. 1999; 281(17):1591-1597.
3. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA and Kantoff PW. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000; 284(10):1280-1283.
4. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25(15):2035-2041.
5. Osanto S and Van Poppel H. Emerging novel therapies for advanced prostate cancer. Ther Adv Urol. 2012; 4(1):3-12.
6. Mukherji D, Eichholz A and De Bono JS. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs. 2012; 72(8):1011-1028.
7. Sotgia F, Martinez-Outschoorn UE and Lisanti MP. Cancer metabolism: new validated targets for drug discovery. Oncotarget. 2013; 4(8):1309-1316.
8. Choi SY, Collins CC, Gout PW and Wang Y. Cancergenerated lactic acid: a regulatory, immunosuppressive metabolite? The Journal of pathology. 2013; 230(4):350-355.
9. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-458.
10. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M and Patel HR. The metastatic cascade in prostate cancer. Surgical oncology. 2006; 15(3):117-128.
11. Clarke NW, Hart CA and Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian journal of andrology. 2009; 11(1):57-67.
12. Chen Z, Ehsanian R and Waes CV. (2009). Nuclear Transcription Factors and Signaling Pathways in Oral Cancer Metastasis. In: Myers J, ed. Oral Cancer Metastasis. (New York: Springer), pp. 197-229.
13. Nebert DW. Transcription factors and cancer: an overview. Toxicology. 2002; 181-182:131-141.
14. Fredericks WJ, Sepulveda J, Lai P, Tomaszewski JE, Lin MF, McGarvey T, Rauscher FJ, 3rd and Malkowicz SB. The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer by controlling a program of ligand dependent SXR target genes. Oncotarget. 2013; 4(7):1075-1092.
15. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA and Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer cell. 2005; 8(5):393-406.
16. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M and Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC cancer. 2007; 7:64.
17. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V and Gerald WL. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer research. 2002; 62(15):4499-4506.
18. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A and Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010; 463(7279):318-325.
19. Pe'er D and Hacohen N. Principles and strategies for developing network models in cancer. Cell. 2011; 144(6):864-873.
20. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R and Califano A. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics. 2006; 7 Suppl 1:S7.
21. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbhandari P, Shen Q, Nemenman I, Basso K, Margolin AA, Klein U, Dalla-Favera R and Califano A. Genomewide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol. 2009; 27(9):829-839.
22. Zheng R and Blobel GA. GATA Transcription Factors and Cancer. Genes & cancer. 2010; 1(12):1178-1188.
23. Vicente C, Conchillo A, Garcia-Sanchez MA and Odero MD. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Critical reviews in oncology/ hematology. 2012; 82(1):1-17.
24. Rodrigues NP, Tipping AJ, Wang Z and Enver T. GATA-2 mediated regulation of normal hematopoietic stem/ progenitor cell function, myelodysplasia and myeloid leukemia. The international journal of biochemistry & cell biology. 2012; 44(3):457-460.
25. Perez-Stable CM, Pozas A and Roos BA. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Molecular and cellular endocrinology. 2000; 167(1-2):43-53.
26. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Cull A, Fazli L, Sharma M, Beltran H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer research. 2013. doi:10.1158/0008-5472.CAN-13-2921-T
27. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW and Wang Y. MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011; 6(9):e24950.
28. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22.
29. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-404.
30. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ and Brown M. A hierarchical network of transcription factors governs androgen receptordependent prostate cancer growth. Molecular cell. 2007; 27(3):380-392.
31. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B and Coetzee GA. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PloS one. 2008; 3(11):e3645.
32. Andreu-Vieyra C, Lai J, Berman BP, Frenkel B, Jia L, Jones PA and Coetzee GA. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Molecular and cellular biology. 2011; 31(23):4648-4662.
33. Geiger B, Tokuyasu KT, Dutton AH and Singer SJ. Vinculin, an intracellular protein localized at specialized sites where microfilament bundles terminate at cell membranes. Proceedings of the National Academy of Sciences of the United States of America. 1980; 77(7):4127-4131.
34. Nagano M, Hoshino D, Koshikawa N, Akizawa T and Seiki M. Turnover of focal adhesions and cancer cell migration. International journal of cell biology. 2012; 2012:310616.
35. Bendas G and Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. International journal of cell biology. 2012; 2012:676731.
36. Nagano M, Hoshino D, Koshiba S, Shuo T, Koshikawa N, Tomizawa T, Hayashi F, Tochio N, Harada T, Akizawa T, Watanabe S, Handa N, Shirouzu M, Kigawa T, Yokoyama S and Seiki M. ZF21 protein, a regulator of the disassembly of focal adhesions and cancer metastasis, contains a novel noncanonical pleckstrin homology domain. The Journal of biological chemistry. 2011; 286(36):31598-31609.
37. Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R and Alaoui-Jamali MA. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. The Journal of experimental medicine. 2010; 207(11):2421-2437.
38. Ezratty EJ, Partridge MA and Gundersen GG. Microtubuleinduced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase. Nature cell biology. 2005; 7(6):581-590.
39. Ghazalpour A, Doss S, Zhang B, Wang S, Plaisier C, Castellanos R, Brozell A, Schadt EE, Drake TA, Lusis AJ and Horvath S. Integrating genetic and network analysis to characterize genes related to mouse weight. PLoS genetics. 2006; 2(8):e130.
40. Langfelder P and Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics. 2008; 9:559.
41. Tung WL, Wang Y, Gout PW, Liu DM, Gleave M and Wang Y. Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate. 2011; 71(7):675-681.
42. Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Molecular cancer therapeutics. 2012; 11(3):775-783.
43. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR and Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 2005; 85(11):1392-1404.
44. Park SY, Nho CW, Kwon DY, Kang YH, Lee KW and Park JH. Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor-1alpha signalling. The British journal of nutrition. 2013; 109(2):210-222.
45. Brett A, Pandey S and Fraizer G. The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells. Molecular cancer. 2013; 12:3.
46. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A and Danesi R. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer metastasis reviews. 2012; 31(3-4):753-761.
47. Bohm M, Locke WJ, Sutherland RL, Kench JG and Henshall SM. A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene. 2009; 28(43):3847-3856.
48. Nishiyama A, Sharov AA, Piao Y, Amano M, Amano T, Hoang HG, Binder BY, Tapnio R, Bassey U, Malinou JN, Correa-Cerro LS, Yu H, Xin L, Meyers E, Zalzman M, Nakatake Y, et al. Systematic repression of transcription factors reveals limited patterns of gene expression changes in ES cells. Scientific reports. 2013; 3:1390.
49. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP. LNCaP model of human prostatic carcinoma. Cancer research. 1983; 43(4):1809-1818.
50. Cheadle C, Vawter MP, Freed WJ and Becker KG. Analysis of microarray data using Z score transformation. The Journal of molecular diagnostics : JMD. 2003; 5(2):73-81.
51. Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thuroff JW and Gleave ME. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castrationresistant prostate cancer progression in vivo. Molecular cancer therapeutics. 2011; 10(2):347-359.
52. Liang CC, Park AY and Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007; 2(2):329-333.
53. Edgar R, Domrachev M and Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research. 2002; 30(1):207-210.